Last month, The New England Journal of Medicine (NEJM) published a new Moderna-sponsored study on the efficacy of the initial bivalent vaccine targeting BA.1 in comparison to the original monovalent booster. The primary focus of the study—antibody titers—shows seemingly positive results.
ORIGINAL LINK